Zacks Investment Management Nuvation Bio Inc. Transaction History
Zacks Investment Management
- $11.4 Billion
- Q3 2024
A detailed history of Zacks Investment Management transactions in Nuvation Bio Inc. stock. As of the latest transaction made, Zacks Investment Management holds 36,125 shares of NUVB stock, worth $88,506. This represents 0.0% of its overall portfolio holdings.
Number of Shares
36,125
Previous 29,731
21.51%
Holding current value
$88,506
Previous $86,000
3.49%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding NUVB
# of Institutions
164Shares Held
157MCall Options Held
3.2KPut Options Held
98.7K-
Decheng Capital LLC Menlo Park, CA26MShares$63.6 Million14.08% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA19.2MShares$47.1 Million1.92% of portfolio
-
Black Rock Inc. New York, NY16.2MShares$39.8 Million0.0% of portfolio
-
Omega Fund Management, LLC Boston, MA13.1MShares$32 Million44.61% of portfolio
-
Octagon Capital Advisors LP New York, NY12.2MShares$29.8 Million6.76% of portfolio
About Nuvation Bio Inc.
- Ticker NUVB
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 217,244,000
- Market Cap $532M
- Description
- Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-422, a small molecule inhibitor targeting cyclin-dependent kinase (CDK)2, CDK4, and CDK6. It is also developing NUV-868, a selective oral small molecule BET inhibitor that e...